Analysis Tools|
Allele Symbol Allele Name Allele ID |
En2tm6Alj targeted mutation 6, Alexandra L Joyner MGI:3831084 |
||||||||||||||||||||
| Summary |
4 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• when given tamoxifen at E10.5, at P21 the anterior region (lobules I-V) is reduced and the central region (lobules VI-VII) is preferentially expanded.
|
|
• when tamoxifen is given at E10.5, at P21 lobule VIII extends more laterally than normal, as do lobules I-V but only on one side
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• following tamoxifen administration at E9.5 - E12.5, all or almost all display an abnormal foliation pattern similar to that in En2 null mice
|
|
• following tamoxifen administration at E9.5 - E12.5, all or almost all display an abnormal foliation pattern similar to that in En2 null mice
|
|
• following tamoxifen administration at E9.5 - E12.5, all or almost all display an abnormal foliation pattern similar to that in En2 null mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• tamoxifen treatment at E9.5, but not at E10.5, results in death at birth
|
|
• when tamoxifen treated at E10.5, at P2 proliferation is similar in the anterior and central lobules, unlike in wild-type mice
|
|
• a major deletion of the midbrain is seen when tamoxifen is given at E9.5, but not when given at E10.5
|
|
• a major deletion of the medial cerebellum is seen when tamoxifen is given at E9.5 but not when given at E10.5
• when given tamoxifen at E10.5, at P14 the distinction between the vermis and the hemispheres is not apparent
|
|
• when given tamoxifen at E10.5, at E12.5 the cerebellar primordium is reduced in size
• when tamoxifen treated at E10.5, development of the vermis prepyramidal fissure is delayed and the order of fissure initiation is altered
|
|
• when given tamoxifen at E10.5, at P14 cerebellar foliation patterns are disrupted
• when given tamoxifen at E13.5 or E14.5, foliation defects in adults are less severe than when tamoxifen is given at E10.5
|
|
• when tamoxifen treated at E10.5, at E18.5 the thickness of the external granule layer was 1.5-2 times greater in the mutants than in wild types
• when tamoxifen treated at E10.5, at P2 the thickness of the external granule layer is similar in the lobules IV/V and VI unlike in wild-type mice
|
|
• when tamoxifen treated at E10.5, at P2 thickness is similar to that at E18.5 and thinner than in the controls.
|
|
• when given tamoxifen at E13.5 or E14.5, in adults the preculminate fissure is absent (between I-II and III) as lobules I-III are fused
• when given tamoxifen at E10.5, at P3 the depth of the primary fissure is increased relative to the intercrural fissure
|
|
• when given tamoxifen at E10.5, at P14 the anterior region (lobules I-V) is reduced and the central region (lobules VI-VII) is preferentially expanded
|
|
• when tamoxifen is given at E10.5, at P14, unlike in wild type, the remnants of lobules I-V extend into the hemispheres
• when tamoxifen is given at E10.5, at P14 remnants of the vermis, specific anterior and posterior regions, are maintained more laterally than in wild-type
• when given tamoxifen at E10.5, at P14 in some mutants lobule VIII is diminished more medially than lobule IX rather than the opposite as occurs in wild-type
• when tamoxifen treated at E10.5, at P2 lobules I - V are smaller and lobule VI is much larger than in wild-type
• when tamoxifen is given at E13.5 or E14.5, in adults lobule VIII is shifted posterior and fused with dorsal lobule IX
• when tamoxifen treated at E10.5, at P2 the thickness of the external granule layer is similar in the lobules IV/V and VI unlike in wild-type mice
|
|
• when given tamoxifen at E10.5, at P14 lobules VI-VII occupy a greater proportion of the vermis than in wild-type
• when given tamoxifen at E10.5, at P14 lobules VIII-IX occupy a smaller proportion of the vermis than in wild-type
• when given tamoxifen at E13.5 or E14.5, in adults lobules I-III are fused into one lobule
|
|
• when tamoxifen treated at E10.5, at P2 overall size of each region, and thus total number of cells, is greatly reduced
|
|
• when given tamoxifen, at P3 the cerebellum is smaller compared to controls
|
|
• when tamoxifen treated at E10.5, at P2 proliferation is similar in the anterior and central lobules, unlike in wild-type mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• when tamoxifen is given at E13.5 or E14.5 in adult preculminate (between I-II and III) as lobules I-III are fused
|
|
• when tamoxifen is given at E10.5, at P14 lobules VI-VII occupied a greater proportion of the vermis than in wild-type
• when tamoxifen is given at E10.5, at P14 lobules VIII-IX occupied a smaller proportion of the vermis than in wild-type
• when tamoxifen is given at E13.5 or E14.5 in adult the vermis has a foliation pattern that was a milder version than that observed in tamoxifen at 10.5 mutants
• when tamoxifen is given at E13.5 or E14.5 in adult posterior region lobule VIII is shifted posterior and fused with dorsal lobule IX.
• when tamoxifen is given at E13.5 or E14.5 in adult lobules I-V and VIII/IX of the vermis were present more laterally than normal tamoxifen at E13.5 or E14.5 in adult lobules I-III were fused into one lobule
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 12/17/2024 MGI 6.24 |
|
|
|
||
